About 23Mofang
23Mofang is a company based in Chengdu (China) founded in 2015. 23Mofang has raised $34.25 million across 5 funding rounds from investors including Hanwang, CD Capital and SBCVC. 23Mofang operates in a competitive market with competitors including CircleDNA, WeGene, GeseDNA, Aijiyin and 1JKT, among others.
- Headquarter Chengdu, China
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$34.25 M (USD)
in 5 rounds
-
Latest Funding Round
$9.65 M (USD), Series B
May 31, 2018
-
Investors
Hanwang
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of 23Mofang
23Mofang has successfully raised a total of $34.25M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $9.65 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $9.7M
- First Round First Round
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2018 | Amount | Series B - 23Mofang | Valuation | CD Capital , SBCVC |
|
| Mar, 2018 | Amount | Series B - 23Mofang | Valuation | Matrix Partners China | |
| Aug, 2017 | Amount | Series B - 23Mofang | Valuation | Hanwang |
Investors in 23Mofang
23Mofang has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Hanwang, CD Capital and SBCVC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
China-based startups are invested in by SBCVC across diverse sectors.
|
Founded Year | Domain | Location | |
|
Tech & Life Science focused early & growth stage VC firm investing in the US & China
|
Founded Year | Domain | Location |
Investments & Acquisitions by 23Mofang
Financial Statements - 23Mofang
23Mofang Comparisons
Competitors of 23Mofang
23Mofang operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CircleDNA, WeGene, GeseDNA, Aijiyin and 1JKT, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Internet-first platform for genetic diagnostics is provided.
|
|
| domain | founded_year | HQ Location |
Genetic testing is conducted using saliva for health risk detection.
|
|
| domain | founded_year | HQ Location |
Gene detection tools and DNA interpretation services are provided.
|
|
| domain | founded_year | HQ Location |
Genetic testing solutions are offered via an online platform.
|
|
| domain | founded_year | HQ Location |
Online platform offering appointment booking services for genetic tests
|
Latest news on 23Mofang
Frequently Asked Questions about 23Mofang
23Mofang was founded in 2015 and raised its 1st funding round 1 year after it was founded.
23Mofang is headquartered in Chengdu, China. It is registered at Chengdu, Sichuan, China.
23Mofang is a funded company, having raised a total of $34.25M across 5 funding rounds to date. The company's 1st funding round was a Series B of $5.95M, raised on Jan 01, 2016.
23Mofang was founded in 2015 in Chengdu, China, within the genetic testing sector. Services are delivered to assess health risks and physical characteristics via genetic analysis. International quality control standards are followed, with global research data incorporated for genetic interpretation. Operations are based in China, supporting users in early health interventions and risk identification.
23Mofang has 9 investors. Key investors include Hanwang, CD Capital, SBCVC, 3E Bioventures Capital, and Matrix Partners China.